Skip to content
Screener

Total Revenue at other companies

Eli Lilly logo
Eli LillyLLY
$22.97B+47.7%
Corcept Therapeutics logo
Corcept TherapeuticsCORT
$256.15M+31.7%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$24.27M+40.4%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$39.66M+53.3%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$214M+28.1%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$266.04M+25.9%

Segments

By product

See full
Recorlev$56.78M+80.6%
Gvoke$22.55M-3.9%
Keveyis$11.68M+1.7%
Royalty, contract and other revenue$1.1M-71.4%
Other product revenue$0-100%

Other financials

Income statement

See full
Gross profit$79.6M+33.4%
Operating income$5.2M+15.4%
Net income-$31.1M-1,513%
EPS (diluted)-$0.18-1,700%

Balance sheet

See full
Cash & equivalents$121.7M+105%
Total debt$289.4M+12.5%
Total equity-$9.7M+49.6%
Total assets$411.9M+23.1%

Cash flow

See full
Operating cash flow$8.3M+4,440%
CapEx$131.0K
Free cash flow-$29.1M

Valuation

See full
Market cap$1.27B+44.5%
Enterprise value$1.44B+33.5%
P/S3.8×+0.2×

Profitability

See full
Gross margin86.6%+4.3pp
Operating margin10.9%+8.4pp
Net margin-5.1%-1.9pp

Returns & leverage

See full
Return on equity-209.8%
Debt / equity19.9×
Current ratio1.4×-0.5×

Where this comes from

Reported directly by Xeris Biopharma Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001867096-26-000065
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Product revenue, net$91,004$67,708$173,458$125,510
Royalty, contract and other revenue1,0963,8311,7696,148
Total revenue92,10071,539175,227131,658
Costs and expenses:
Cost of goods sold12,51211,89823,08620,626
Research and development10,6698,05519,45215,808
Selling, general and administrative61,03544,393114,17988,411
Amortization of intangible assets2,7112,7115,4215,421

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Xeris Biopharma Holdings, Inc.'s total revenue?
Xeris Biopharma Holdings, Inc. (XERS) reported total revenue of $92.1M in Q2 2026.
How has Xeris Biopharma Holdings, Inc.'s total revenue changed year-over-year?
Xeris Biopharma Holdings, Inc.'s total revenue increased by 28.7% year-over-year, from $71.54M to $92.1M.
What is the long-term trend for Xeris Biopharma Holdings, Inc.'s total revenue?
Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s total revenue has grown at a 55.8% compound annual growth rate (CAGR), from $49.59M to $291.85M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Xeris Biopharma Holdings, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude